Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNT166a Mpox mRNA Vaccine in Healthy Participants
NCT07379580Phase 2Recruiting
- Sponsor
- BioNTech SE
- Start
- Feb 2026
- Primary completion
- Jun 2027
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 2
01
Overview
A Phase 2 trial of BNT166 in mpox, smallpox, Orthopoxvirus infection, sponsored by BioNTech SE. Started Feb 2026; status: recruiting.
02
Drugs
BNT166
03
Conditions
mpoxsmallpoxOrthopoxvirus infection
Beyond the preview
Go deeper on NCT07379580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07379580.